Gracillin overcomes osimertinib resistance in NSCLC via dual inhibition of EGFR and Mcl-1
- 19 March 2026
- journal article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 33 (6) , 673-684
Abstract
The advent of molecularly targeted therapies has revolutionized the clinical management of non-small cell lung cancer (NSCLC), substantially expanding therapeutic options. Nevertheless, significant clinical challenges persist, including acquired resistance, treatment-related toxicities, and economic burdens, underscoring the need for novel therapeutic strategies. In this study, we identified a promising epidermal growth factor receptor (EGFR)-targeting natural product, Gracillin. Unlike osimertinib's selective profile, Gracillin possesses broad-spectrum efficacy against both EGFR-mutant (including Ex19del, L858R, and T790M variants) and wild-type (WT) NSCLC. Mechanistically, Gracillin-mediated EGFR inhibition suppresses Akt signaling, leading to GSK3β-dependent phosphorylation of Mcl-1 at Ser159. This post-translational modification promotes β-TRCP-mediated K48-linked polyubiquitination and degradation of Mcl-1, thereby reducing its protein levels and subsequently inducing apoptosis. In vitro, Gracillin reduced cell viability by up to 90% (IC₅₀ ≈ 1.4-2.78 µM) in both EGFR-mutant and WT NSCLC cell lines. Notably, in vivo studies corroborated these findings, with Gracillin demonstrating significant tumor growth inhibition of up to 60% in both osimertinib-sensitive and -resistant NSCLC models. The compound's unique ability to target diverse EGFR genotypes while overcoming TKI resistance suggests its potential as a therapeutic agent with a strong rationale for further clinical development.Keywords
This publication has 49 references indexed in Scilit:
- Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and Uncommon Mutations in NSCLC: A Brief ReportJournal of Thoracic Oncology, 2024
- Anti-apoptotic MCL-1 promotes long-chain fatty acid oxidation through interaction with ACSL1Molecular Cell, 2024
- Advances and challenges in the treatment of lung cancerBiomedicine & Pharmacotherapy, 2023
- Anticancer Potential of the Plant‐Derived Saponin Gracillin: A Comprehensive Review of Mechanistic ApproachesChemistry & Biodiversity, 2023
- Gastrodin destabilizes survivin and overcomes pemetrexed resistanceCellular Signalling, 2023
- Gracillin relieves pulmonary fibrosis by suppressing the STAT3 axisJournal of Ethnopharmacology, 2023
- Non‐small cell lung cancer in ChinaCancer Communications, 2022
- Curcumin–phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in ratsInternational Journal of Pharmaceutics, 2007
- Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholineCancer Chemotherapy and Pharmacology, 2006
- Glycogen Synthase Kinase-3 Regulates Mitochondrial Outer Membrane Permeabilization and Apoptosis by Destabilization of MCL-1Molecular Cell, 2006